Evialis announces three new acquisitions - 13/03
The Evialis group, an international specialist in animal nutrition and health, has announced two acquisitions in France and South Africa and the purchase of the minority stakeholding held by its historical partner in India.
Reflecting group strategy, these transactions concern differentiated activities such as horse feed and specialities. Two of them concern geographical areas with strong growth potential.
Consolidating a leading position in horse feed
Evialis recently signed a leasing-management agreement for the horse feed business sold under the Extral brand by Piètrement (based in Provins). The Extral brand represents an annual volume of around 6,000 tonnes, intended primarily for a customer base of riding centres in the Paris area.
Extral will reap the full benefits of a leading position on the horse feed market in France.
The Evialis group produces and sells more than 80,000 tonnes of horse feed per year in France through its main brands, which include Royal Horse, UAR, Purina and Derby. More than one in three horses eating manufactured feed consume a product from one of the brands of the Evialis group.
Acquisition of a minority stakeholding in India
In India, the group has signed a memorandum of understanding to acquire the 35% minority stakeholding held by its local partner in Nutech. With this operation, Evialis owns 100% of its Indian subsidiary.
At end 1998, the Evialis group opened an industrial plant in the region of Mumbai producing premix and concentrates, primarily for the poultry market. This subsidiary reported turnover of €2.3 million last year.
Stepping up development in south africa
In the promising South African market, Evialis recently acquired Progress Feed. Coprex, the local Evialis subsidiary, has been engaged in industrial cooperation with this firm for a number of years.
Progress Feed produces 10,000 tonnes/year of specialities and extruded products for young animals and pets.
This operation follows a promising start in South Africa, and Evialis is now stepping up the pace of its development, which is based on sales of premix and nutritional specialities.
These transactions reflect the targeted external growth policy of the Evialis group.